Yuanyuan XIAO,Carlos BAIS,YounJeong CHOI,Nicola C. CONSALVO
申请号：
US15581448
公开号：
US20170226198A1
申请日:
2017.04.28
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
